Zydus Lifesciences (NSE:ZYDUSLIFE) filed the transcript of its Q1 FY27 post-results earnings call on 18 August 2026, pursuant to SEBI Listing Regulations 30 and 46(2)(oa). The call, held on 11 August 2026, disclosed consolidated revenues of Rs 80.2 billion for the quarter ended 30 June 2026, representing 22% year-on-year growth.
Key Highlights
- Consolidated revenues for Q1 FY27 rose 22% year-on-year to Rs 80.2 billion, with EBITDA of Rs 19.3 billion and an EBITDA margin of 24.1%.
- Net profit for the quarter stood at Rs 9.4 billion, while the net debt to EBITDA ratio was 0.7 times as on 30 June 2026.
- The company launched NufymcoTM Injection (Ranibizumab biosimilar) in the US market and completed the acquisition of Assertio Holdings during the quarter.
- The USFDA granted priority review to the new drug application for Saroglitazar Magnesium for primary biliary cholangitis treatment.
About the Company
Zydus Lifesciences Limited (NSE:ZYDUSLIFE), headquartered in Ahmedabad, Gujarat, is a fully integrated pharmaceutical company operating across branded formulations, generics, consumer wellness, medical devices, and novel drug discovery. The company serves patients across India, the United States, Europe, and emerging markets, and is listed on both NSE and BSE under code 532321. Its flagship innovative product, Lipaglyn (Saroglitazar), is the world's first approved Saroglitazar-based therapy for diabetic dyslipidemia.
Announcement in Detail
During the Q1 FY27 earnings call, management reported that India branded formulations grew 20% year-on-year, outperforming the market across cardiology, diabetology, gynecology, anti-infectives, pain management, oncology, and nephrology. The chronic and sub-chronic portfolio share reached 54.2% of domestic formulations revenue as per AWACS MAT June 2026, reflecting a 360 basis point improvement over four years. International markets formulations posted revenues of Rs 9.7 billion, up 34% year-on-year, while North America revenues stood at Rs 31 billion, up 5% quarter-on-quarter.
The Consumer Wellness business reported revenues of Rs 14.3 billion, up 67% year-on-year, driven by the inclusion of the Comfort Click portfolio, which delivered like-to-like international growth of 25%. The company also entered a joint venture with Sunshine Healthcare to establish a pharmaceutical manufacturing facility in Sri Lanka. On the regulatory front, its injectable facility at Zydus Biotech Park received an Establishment Inspection Report with a Voluntary Action Indicated classification following a GMP surveillance inspection conducted in April and May 2026.
Impact on Investors
The filing shows that branded products now account for over 55% of total Q1 FY27 revenues, and management stated on the call that this share is expected to exceed two-thirds of overall revenue over the medium term, subject to execution. Shareholders will observe that the net debt to EBITDA ratio of 0.7 times indicates a relatively conservative leverage position as disclosed. The completion of the Assertio Holdings acquisition and the NufymcoTM biosimilar launch in the US represent concrete changes to the company's commercial footprint, the financial terms of which investors should review in the detailed quarterly results filing separately.
Sector / Market Context
India's pharmaceutical industry is among the largest globally by volume, with the domestic formulations market tracked monthly by AWACS and IQVIA. The US generics market, a key revenue driver for Indian pharma exporters, continues to see volume-led competition, while the biosimilar segment is gaining regulatory traction under the USFDA's Biosimilar Action Plan. India's MedTech sector is also expanding, supported by the government's Production Linked Incentive scheme for medical devices introduced in recent years, providing a supportive policy backdrop for companies diversifying into devices and specialty products.